Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and NeckJennifer L. Leddon, Trisha M. Wise‐Draper, Shuchi Gulati et al.|Clinical Cancer Research|2022Cited by 26
Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapySulsal Haque, Nooshin Hashemi-Sadraei|Drug Design Development and Therapy|2017Cited by 7
Adjuvant nivolumab following salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy: A single-arm phase II multi-institutional study.Jennifer L. Leddon, Trisha M. Wise‐Draper, Brian Cervenka et al.|Journal of Clinical Oncology|2021Cited by 5
Data from Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and NeckJennifer L. Leddon, Trisha M. Wise‐Draper, Shuchi Gulati et al.|Unknown|2023Cited by 1
Data from Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and NeckJennifer L. Leddon, Trisha M. Wise‐Draper, Shuchi Gulati et al.|Unknown|2023Cited by 0